Session (CTI)

Hosted by the ISPOR Institute for Healthcare Transformation, this forum explores how evidence of value can be translated into sustainable implementation within real-world health systems. A moderated panel will bring together complementary perspectives shaping coverage decisions for GLP-1 therapies. The HEOR perspective will frame the evidence base for coverage, including cost-effectiveness, budget impact, and outcomes modeling adapted to regional settings. The health systems perspective will shift the discussion from whether therapies should be covered to whether systems can support appropriate initiation, follow-up, supply forecasting, prescribing governance, and equity monitoring. The policy and payer perspective will examine how these considerations translate into phased adoption, conditional coverage, and governance mechanisms.